Patent: 8,597,655
✉ Email this page to a colleague
Summary for Patent: 8,597,655
Title: | Recombinant fusion protein and polynucleotide construct for immunotoxin production |
Abstract: | The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing. |
Inventor(s): | Barnea; Itay (Yavne, IL), Benhar; Itai (Rehovot, IL), Ben-Yosef; Rahamim (Mevaseret-Zion, IL), Vexler; Akiva (Hod Hasharon, IL) |
Assignee: | Ramot at Tel-Aviv University Ltd. (Tel Aviv, IL) The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (Tel Aviv, IL) N/A (N/A) |
Application Number: | 13/239,847 |
Patent Claims: | see list of patent claims |
Details for Patent 8,597,655
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2027-05-10 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2027-05-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |